Alvotech (NASDAQ: ALVO) announced this week that the FDA has accepted for review a Biologics License Application for AVT16, the Reykjavik-based biosimilar developer's proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration. The acceptance marks a significant regulatory step in the effort to introduce lower-cost competition into the biologics segment of the inflammatory bowel disease (IBD) treatment market.
Vedolizumab is a gut-selective integrin antagonist that works by blocking the α4β7 integrin receptor, limiting migration of pro-inflammatory lymphocytes to the gastrointestinal tract. The mechanism has made the reference biologic a cornerstone therapy for moderate-to-severe Crohn's disease and ulcerative colitis — conditions that affect an estimated 3 million adults in the United States alone. Alvotech's biosimilar candidate is formulated as a lyophilized vial for intravenous administration, mirroring the originator's dosing route, and has been designated as a proposed interchangeable biosimilar, the highest regulatory standard the FDA grants to such products.
While vedolizumab is a prescription biologic rather than a dietary supplement or functional ingredient, its regulatory trajectory carries direct relevance for practitioners, dietitians, and operators working at the clinical nutrition and medical food interface. IBD patients represent a high-priority consumer segment for gut-health-positioned functional foods, medical nutrition products, and condition-specific nutraceutical formulations — a category that market analysts have valued in the multi-billion dollar range and that continues to attract ingredient investment from probiotic, prebiotic, and anti-inflammatory botanical suppliers. Greater formulary access to affordable biologic therapy could expand the addressable patient population reaching remission, opening a larger opportunity for complementary functional nutrition positioning.
For nutraceutical and functional food brands operating in the gut-health space, the biosimilar pipeline is worth monitoring as a downstream market signal. As biologic costs decrease and IBD patients achieve better disease control, demand for maintenance-phase dietary support — including high-CFU probiotic finished formulations, postbiotics, and anti-inflammatory omega-3 and curcumin products — is expected to grow. Brands with structure-function claims targeting digestive comfort, microbiome balance, or gut-barrier integrity are increasingly positioning alongside clinical care pathways rather than in opposition to them.
Alvotech has not disclosed a PDUFA target action date, but FDA acceptance of the BLA confirms the submission met the agency's threshold for completeness and will proceed through formal review. Industry observers tracking the biosimilar and regulatory pipeline will note that interchangeability designation, if ultimately granted, would allow pharmacists to substitute AVT16 without prescriber intervention — a meaningful commercial differentiator in a competitive biologics marketplace.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.